Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 13, 2026 · Filed Nov 13, 2026
The CFO of Abcellera Biologics paid $97K out of pocket for Abcellera Biologics shares. 1 other person at Abcellera Biologics bought some too, in the same month. It was the first purchase in over a year.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$97,438
Shares × reported transaction price
$25K–$100K
+1.8%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
None in 20 months of history
Confirmed open-market purchases by the same insider in the available history
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 3.6% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($2.68M)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-29. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
4 days after results of Nov 9, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $11.49 on Nov 13, 2026, 313% above its 52-week low and 22% below its high, after a 16% drop over the previous 30 trading days
52-week range $2.78 (Feb 5, 2026) to $14.82 (Sep 29, 2026), 72% of the way up, from 250 adjusted closes. 30 trading days earlier: $13.74 on Oct 2, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Andrew Booth's first purchase of ABCL since May 2023
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
Insider filing
Traded Nov 13 · filed the same day
Gift or transfer — classified separately from trades.
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider buying
First insider buy since Mar 2025Traded Nov 12 · filed the same day
A major shareholder of Abcellera Biologics paid $699K out of pocket for Abcellera Biologics shares. 1 other person at Abcellera Biologics bought some too, in the same month. It was the first purchase in 20 months.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
